0001479290-23-000080.txt : 20230620
0001479290-23-000080.hdr.sgml : 20230620
20230620162504
ACCESSION NUMBER: 0001479290-23-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kolaja Carey OConnor
CENTRAL INDEX KEY: 0001848717
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 231025433
MAIL ADDRESS:
STREET 1: C/O REVANCE THERAPEUTICS, INC
STREET 2: 1222 DEMONBREUN STREET, SUITE 1001
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wf-form4_168729267524879.xml
FORM 4
X0407
4
2023-06-15
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001848717
Kolaja Carey OConnor
C/O REVANCE THERAPEUTICS, INC
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
1
0
0
0
1
Common Stock
2023-06-15
4
M
0
2500
18.12
A
19061
D
Common Stock
2023-06-15
4
S
0
2500
28.24
D
16561
D
Stock Option (Right to buy)
18.12
2023-06-15
4
M
0
2500
0
D
2032-05-03
Common Stock
2500.0
8256
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2023 by Ms. Kolaja.
The shares subject to the stock option vested on May 4, 2023.
/s/ Dwight Moxie, Attorney-in-Fact
2023-06-20